Azemiopsin is a linear peptide from the viper Azemiops feae venom. It has high affinity and selective inhibitor of the muscle nicotinic acetylcholine receptor (nAChR) and can be considered as a potentially useful nondepolarizing muscle relaxant. This peptide does not contain disulfide bonds, which facilitates its synthesis and modification in comparison with other snake neurotoxins. Within the framework of the State Contract No. 14.N08.12.1025 of April 28, 2015, "Preclinical studies of a polypeptide blocking neuromuscular transmission-based drug for the treatment of muscular dystonia", a study was conducted of the preclinical profile of azemiopsin for in vitro and in vivo efficacy, acute and chronic toxicity, pharmacokinetics, allergenic ability, immunotoxicity and mutagenic activity. The peptide showed high efficiency of muscle relaxation with intramuscular injection in mice. The peptide did not possess immunotoxic, allergenic or mutagenic properties. In general, the results show that azemiopsin has good drug-like properties for use as a local muscle relaxant and in its parameters is not inferior to the relaxants that are currently used. However, rodent tests do not provide enough information on the distribution of azemiopsin molecules in muscle tissue, as well as the applicability of this muscle relaxant in various surgical operations that require different durations of action and release rates of the drug. There is always the possibility that real surgery may exhibit properties that were not predicted by preclinical testing. Within the framework of the proposed project, we plan to carry out a research study consisting of the synthesis of several azemiopsin derivatives with presumably altered pharmacokinetic and pharmacodynamic properties, obtaining characteristics of their interaction with mammalian muscle nAChRs in vitro, and researching the properties of the azemiopsin and its new derivatives in surgical operations on individual representatives of ruminant and/or non-ruminant artiodactyls. The advantage of working with relatively large animals is their greater similarity with humans, the possibility of estimating the distribution and biodegradation of the studied molecules more carefully than in the case of rodents and rabbits. The implementation of such a project is possible only within the framework of a hybrid study involving the interaction of biochemical and veterinary teams that can together perform a full cycle of work from the rational design of new aziompsin derivatives, their synthesis and in vitro testing, before testing large animals with monitoring of various biological parameters.